Competition Damages Claims: How Victims Recover and What Infringers Face

Private enforcement of competition law turns public decisions into money — in both directions. Companies that bought from a cartel or were foreclosed by a dominant supplier hold claims they rarely quantify; companies that infringed face a decade-long tail of litigation across multiple jurisdictions. This guide covers the claim types, the procedural tools, quantification, funding and defence — closing the compliance pillar of our Competition & Antitrust hub.

What types of claims exist — and who brings them?

Follow-on claims ride an existing infringement decision: liability is established, and the fight is causation and quantum. They dominate the docket because they are cheaper and more certain. Standalone claims prove the infringement themselves — used where no authority has acted, notably in abuse cases brought by foreclosed rivals who cannot wait years for an enforcer.

Claimant types shape strategy. Direct purchasers hold the cleanest claims (overcharge on their own invoices). Indirect purchasers must trace pass-on through the chain, and defendants may run the passing-on defence against direct purchasers — a symmetry the Directive codified. Foreclosed competitors claim lost profits and lost enterprise value, harder to quantify but larger per claimant. Collective vehicles aggregate small claims: the UK’s opt-out class actions before the Competition Appeal Tribunal (the Merricks/Mastercard line established their viability), Dutch claim foundations, and Germany’s assignment models. Public bodies increasingly sue as purchasers — rigged-tender recovery is now a standard procurement discipline, as our bid-rigging guide notes.

What procedural tools decide these cases?

Binding decisions: a final Commission decision binds all EU national courts; national authority decisions bind their own courts and are prima facie evidence elsewhere. That single rule converts most follow-on litigation into a quantum dispute. Disclosure: the Directive requires proportionate disclosure of evidence, with a graduated protection regime — leniency statements and settlement submissions are absolutely protected, investigation files are protected until proceedings close, pre-existing documents are disclosable.

Limitation: at least five years from when the claimant knew or should have known of the infringement, harm and infringer’s identity, suspended during investigations — which is why claims arrive years after decisions and why defendants cannot plan for closure. Jurisdiction: claimants forum-shop within Europe (England, the Netherlands and Germany compete for cases on procedure, disclosure and funding), often anchoring on a local subsidiary to sue a whole group. Add third-party litigation funding, now a mature market pricing competition claims as an asset class, and the structural picture is clear: the barriers that made private enforcement theoretical in Europe are gone.

How is harm quantified?

By comparison. The workhorse method is before-and-after (prices during the infringement versus a clean period), refined by yardstick comparisons (unaffected geographic or product markets) and difference-in-differences regressions controlling for cost and demand shocks. Cost-based and simulation models supplement where data is thin. The Commission’s practical guide and national courts’ growing expertise have made these disputes technical but tractable — and courts routinely apply broad discretion where precision is impossible rather than dismissing claims.

Two multipliers matter more than the percentage. Interest: awarded from the date of each overcharged purchase, which over ten to fifteen years can exceed the principal — and is the reason early settlement is often cheaper than a defensible quantum position. Pass-on: defendants argue the claimant passed the overcharge downstream; claimants answer with volume-effect losses (higher prices lost them sales). Both sides need transactional data, which is why claimants who preserved procurement records win faster and defendants who cannot reconstruct their own pricing history negotiate from weakness.

How should victims pursue claims — and defendants manage them?

Victims: start with an exposure audit. Identify purchases from any decided cartel in your supply chain (published decisions name products and periods), preserve procurement records, quantify preliminarily, and check limitation in each candidate forum — claims worth pursuing are routinely abandoned because nobody looked. Then choose the vehicle: individual action, assignment to a claims vehicle, or joining a collective proceeding, weighing control against cost. Funding is available for meritorious claims at portfolio scale, and settlement — not judgment — resolves the large majority.

Defendants: model the tail at the moment of the decision, not when the first claim arrives; centralise defence across jurisdictions to avoid inconsistent positions; preserve and organise transactional data early (the defence’s quantum case is built from it); and coordinate with co-infringers on contribution while managing the conflicts leniency status creates. Settle strategically — early settlements with major customers cap interest and preserve relationships, which is often the commercial priority that outranks litigation economics. And feed the experience back into the compliance program: the total-cost number the damages tail produces is the most persuasive compliance-budget argument any general counsel will ever have.

How does litigation funding change the landscape?

Decisively, by removing the cost barrier that kept European private enforcement theoretical. Funders now underwrite competition claims as an asset class — meeting costs and adverse-costs risk for a share of recovery — which makes viable both individual mid-size claims and the collective proceedings whose economics depend on scale. The UK’s CAT regime, Dutch foundations and German assignment models all rely on funded structures.

The consequences run both ways. Claimants get access to expert economics and disclosure fights they could not otherwise fund. Defendants face better-resourced opponents and more claims, and must factor funding availability into settlement strategy — a funded claimant has staying power a distressed customer does not. Regulatory attention to funding terms (including UK litigation on funder agreements) adds uncertainty at the margins, but the structural shift is settled: the money to sue exists now, and infringement decisions are read by an industry looking for it.

What does the interaction between public and private enforcement mean strategically?

That every public-enforcement decision is also a private-liability decision, and should be litigated as such. Settlement admissions ease claimants’ path; contested fights that narrow duration or affected-sales findings shrink the damages base as well as the fine; leniency buys immunity from one and only limited relief from the other. Defence strategy that optimises the fine while ignoring the damages tail routinely picks the worse of the two paths, as several settled cartel participants discovered when their admissions anchored claims worth multiples of the saved fine.

The corollary for compliance economics is powerful: when the board weighs a program’s cost, the honest comparator is fine plus damages plus defence plus remediation plus distraction — the full lifecycle number that our fine arithmetic only begins. Presented that way, competition compliance stops being a legal overhead and becomes what it actually is: the cheapest available insurance against the largest single loss most companies can suffer.

What claims arise outside cartels?

A growing share. Abuse-of-dominance claims by foreclosed rivals — margin squeeze, refusal to supply, exclusivity — are standalone-capable and can be brought with interim relief where the claimant’s survival is at stake, which is often the only remedy that arrives in time. Distributors and franchisees sue over unlawful vertical restraints (resale-price maintenance, territorial restrictions). Business users of platforms now sue on DMA obligations directly, without waiting for the Commission, as our DMA enforcement guide notes.

These claims are harder than follow-on cartel actions — liability must be proved — but they carry strategic value beyond damages: an injunction restoring supply or access can save a business, and a filed claim frequently produces a commercial settlement that a regulatory complaint never would. Businesses treating competition law purely as a compliance burden overlook that it is also, quite practically, a commercial remedy available to them.

What should a board ask after any adverse decision?

Four questions, immediately: what is our modelled damages exposure by jurisdiction and claimant class, including interest to a realistic settlement date? Which of our own records do we need preserved and organised to defend quantum? Where are we exposed to inconsistent positions across parallel proceedings? And what is the settlement strategy with our largest customers, who are simultaneously our claimants and our commercial future?

Boards that ask these in month one settle better and cheaper than boards that treat the fine as the conclusion of the matter. The damages phase rewards preparation asymmetrically, because interest runs against the defendant throughout — every quarter of delay has a price, and it is usually larger than the legal fees being economised.

Frequently Asked Questions